查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1247444

2023-2030 年全球经颅磁刺激器市场

Global Transcranial Magnetic Stimulator Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

经颅磁刺激器的全球市场规模预计到 2022 年将达到 112525 万美元，到 2030 年将达到 224479 万美元，在预测期内（2023-2030 年）增长 9.2%。预计将以复合年增长率。

经颅磁刺激疗法是一种非侵入性技术，涉及应用短磁脉衝来激发与重度抑郁症、阿尔茨海默氏症、帕金森氏症和其他神经系统疾病相关的大脑区域的神经元。突破。

市场动态

在预测期内，越来越多的老年人口、越来越多的与年龄相关的神经系统疾病以及产品的发布和批准正在推动经颅磁神经刺激市场的全球增长。

在预测期内，众多产品的发布和批准推动了全球市场的增长。

在预测期内，产品发布和批准等市场发展正在推动全球经颅磁刺激设备市场的增长。 例如，2022 年 7 月，FDA 批准了 Neuronetics 的 NeuroStar Advanced Therapy for Mental Health，一种经颅磁刺激设备，用于治疗重度抑郁症患者的焦虑症状。 同样，在 2021 年 8 月，美国 FDA 批准了一家先进的非侵入性神经刺激治疗供应商，用于治疗精神健康状况，以减少成年患者伴有抑郁症的焦虑症状，也称为焦虑抑郁症。获得批准的深度经颅磁刺激（深度 TMS）系统BrainsWay Ltd. 的营销许可 同样，2020 年 8 月，FDA 批准 Magventure 的 TMS 疗法作为强迫症（OCD）的辅助治疗。 这是丹麦医疗设备製造商 MagVenture 在美国的第二个适应症。

此外，2021 年 11 月，基于神经科学的精神保健和研究公司 Magstim 获得了 Horizo□□n 3.0 的 510K 许可。 Horizo□□n 3.0 专为临床环境设计，通过导航 TMS 和分析提供增强的工作流程。 此外，Magstim Connect 是一种独特的集中式 TMS 患者数据管理解决方案，有望在不久的将来推动市场增长。 因此，在预测期内，越来越多的产品批准和推出正在推动全球经颅磁刺激设备市场。

TMS 的高成本很可能会抑制全球经颅磁刺激设备市场的增长。

然而，经颅磁刺激设备的高成本预计将在预测期内抑制全球市场的增长。 例如，TMS 机器的成本高达 60,000 美元，使大多数个人或从业者无法承受，阻碍了预测期内全球市场的增长。

COVID-19 的影响

COVID-19 对全球经颅磁刺激设备市场产生了重大影响，因为大流行直接影响了需求和生产，增加了公司的财务负担。 在大流行期间，神经科手术经常被推迟或取消，以阻止 COVID-19 的传播。 受影响最严重的美国、俄罗斯、印度、巴西、法国、英国、意大利和西班牙的神经外科手术减少了约 55%。 COVID-19 病毒会伤害心臟、肺和大脑，并可能导致长期健康问题。 然而，由于社会孤立，COVID-19 增加了抑郁和焦虑的病例，在一定程度上抵消了大流行的负面影响。

内容

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 批量产品发布和批准
      • 老年人口和随之而来的神经系统疾病的增加
    • 约束因素
      • 设备成本高
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第 6 章 COVID-19 分析

  • 市场上 COVID-19 的分析
    • 在 COVID-19 市场情景之前
    • 当前的 COVID-19 市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第 7 章按应用程序类型

  • 阿尔茨海默氏痴呆症
  • 抑郁症
  • 帕金森病
  • 癫痫症
  • 其他

第 8 章按类型

  • 深度经颅磁刺激
  • 重复经颅磁刺激
  • 其他

第 9 章最终用户

  • 医院
  • 门诊手术中心
  • 其他

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准

第12章公司简介

  • 头脑风暴
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Magstim
  • Neurosoft
  • MAG & More GmbH
  • Salience TMS Neuro Solutions
  • eNeura Inc.
  • Nexstim, Inc
  • Magventure
  • Eneura
  • Axilum Robotics

第13章 DataM

简介目录
Product Code: MD1678

Market Overview

The global Transcranial Magnetic Stimulator Market size was valued at US$ 1,125.25 million in 2022 and is estimated to reach US$ 2,244.79 million by 2030, growing at a CAGR of 9.2% during the forecast period (2023-2030).

Transcranial Magnetic Stimulation is a noninvasive technological breakthrough involving applying short magnetic pulses to elicit nerve cells in brain regions associated with major depression, Alzheimer's, Parkinson's and other neurology disorders.

Market Dynamics

The growing geriatric population and increase in age-related neurological disorders, along with product launches and approvals, are boosting the global transcranial magnetic nerve stimulation market growth during the forecast period.

A large number of product launches and approvals drive the forecast period's global market growth.

The growing market developments, such as product launches and approvals, are driving the global transcranial magnetic stimulator market growth during the forecast period. For instance, in July 2022, the FDA approved Neuronetics's NeuroStar Advanced Therapy for Mental Health, a transcranial magnetic stimulation device for treating anxiety symptoms in individuals with major depressive disorder. Likewise, in August 2021, the U.S. FDA approved Deep Transcranial Magnetic Stimulation (Deep TMS) System marketing clearance to BrainsWay Ltd., a supplier of advanced noninvasive neurostimulation treatments for mental health conditions, to lessen anxiety comorbid manifestations with depression in adult patients, also called anxious depression. Similarly, in August 2020, the FDA granted clearance to MagVenture's TMS Therapy for the adjunct treatment of the obsessive-compulsive disorder (OCD). It is the second indication in the U.S. for the Danish medical device company MagVenture.

Moreover, in November 2021, Magstim, a neuroscience-based mental health care and research provider received 510K clearance for Horizon 3.0. Horizon 3.0 delivers enhanced workflows with navigated TMS and analytics since it was particularly designed for the clinical setting. Thereby delivering connected care at networked sites, Magstim Connect is a unique and concentrated patient data management solution for TMS, which is anticipated to enhance market growth in the near future. Therefore, the growing product approvals and launches are boosting the global transcranial magnetic stimulators market during the forecast period.

The high cost of the TMS will likely restrain the growth of the global transcranial magnetic stimulator market.

However, the high cost of the transcranial stimulator machine will restrain the global market growth during the forecast period. For instance, a TMS machine may cost up to $60,000, leaving most individuals or practitioners unable to buy, hampering the global market growth during the forecast period.

COVID-19 Impact

COVID-19 significantly impacted the global transcranial magnetic stimulators market, as the pandemic directly impacted demand and production and raised the financial burden on firms. Neurological procedures were frequently delayed or canceled to stop the spread of COVID-19 during the pandemic. The most-affected nations, the U.S., Russia, India, Brazil, France, the U.K., Italy, and Spain, observed around a 55% decline in neurosurgical procedures. The COVID-19 virus can harm the heart, lungs, and brain, which raises the possibility of long-term health issues. However, COVID-19 has led to an increase in cases of depression and anxiety owing to social isolation, which has somewhat neutralized the negative impact of the pandemic.

Segment Analysis

The devices segment is expected to dominate the market throughout the forecast period (2023-2030).

The growing cases of Alzheimer's worldwide and new research developments about TMS in Alzheimer's are boosting the segment growth during the forecast period. For instance, according to Alzheimer's Disease International, someone develops dementia every 3 seconds. There were more than 55 million people worldwide with dementia in 2020. This number will increase nearly twice every 20 years, achieving about 78 million in 2030 and around 139 million in 2050. Considerably the upsurge will be in developing nations. Over 60% of individuals with dementia live in low and middle-income nations, while by 2050, this will increase to roughly 71%. The most rapid growth in the elderly population occurs in China, India, and their south Asian and western Pacific neighbors. Dementia primarily affects older people, although there is a growing understanding of cases that begin before age 65.

Moreover, according to the WHO, above 55 million people live with dementia globally, and there are almost 10 million new cases yearly. Alzheimer's disease is the most typical dementia and makes up 60-70% of cases. Also, according to the BrightFocus, a tax-exempt nonprofit organization, the percentage of people with Alzheimer's boosts with age: about 5% of people aged 65 to 74, around 13% of people aged 75-84, and almost 33% of people aged 85 and older have Alzheimer's dementia. Furthermore, new research suggests that the novel approach to repetitive transcranial magnetic stimulation (rTMS) that targets the precuneus appears to slow the progression of cognitive and functional decline in individuals with Alzheimer's disease (AD). Thus, from the data mentioned the TMS application in Amlzhimers will dominate the global transcranial stimulators market throughout the forecast period.

Geographical Analysis

The North American region holds the largest global Transcranial Magnetic Stimulator Market share.

North America dominates the global transcranial stimulators market owing to the increasing geriatric population, different organizations spreading awareness about neurological disorders, the growing cases of neurological disorders in this region and the presence of better reimbursement policies. For instance, according to America's Health Rankings Senior Report 2021, over 54 million adults aged 65 and older live in the U.S., accounting for approximately 16.5% of the nation's population. The number of older adults in the U.S. is expanding, and by 2050, the total number of adults ages 65 and older is projected to rise to an estimated 85.7 million, roughly 20% of the overall U.S. population. Moreover, according to the Alzheimer's Association, more than 6 million Americans are living with Alzheimer's, which is expected to reach almost 13 million by 2050. That is, 1 in 3 seniors dies with Alzheimer's or another dementia. It kills more than breast cancer and prostate cancer combined. In 2022, Alzheimer's and other dementias were estimated to cost the nation $321 billion, and these costs were anticipated to reach nearly $1 trillion by 2050. Furthermore, transcranial magnetic stimulation therapy is reimbursed by Medicare.gov if provided by the use of a device approved by the FDA to supply TMS. Therefore, from the data mentioned above, it is estimated that North America will hold most of the global transcranial magnetic stimulation market throughout the forecast period.

Competitive Landscape

The Transcranial magnetic stimulator market is moderately competitive due to the new market entrants and favorable regulatory policies. Some key players are Brainsway, Magstim, Neurosoft, MAG & More GmbH, Salience TMS Neuro Solutions, eNeura Inc., Nexstim Inc, Magventure, Eneura, and Axilum Robotics., among others. These key players hold the major share of the market through innovations, product launches, collaborations, acquisitions, and alliances. For instance, in March 2021, MagVenture launched the MagVenture Flow Arm, a patent-pending clinical positioning system developed to enhance the delivery of MagVenture's FDA-cleared protocols for noninvasive brain stimulation technology for the treatment of major depressive disorder and as an adjunct therapy for the obsessive-compulsive disorder (OCD).

BrainsWay

Overview:

BrainsWay is an international company committed to developing a medical device that utilizes H-coil for deep transcranial magnetic stimulation as a non-invasive therapy for depression, OCD, and smoking addiction. The company was established in 2003 and is headquartered in Massachusetts, United States.

Product Portfolio:

BrainsWays' transcranial magnetic stimulator product portfolio has Deep TMS: A revolutionary depression treatment that has transformed the mental healthcare field, Deep TMS has been FDA-approved for safely and effectively treating Major Depressive Disorder (MDD) through BrainsWay's patented H-coil technology..

The global transcranial magnetic stimulator market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. A Large Number of Product Launches and Approvals
      • 4.1.1.2. Growing Geriatric Population and Associated Neurological Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of device
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 7.1.2. Market Attractiveness Index, By Application Type
  • 7.2. Alzheimer's Disease
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 7.3. Depression
  • 7.4. Parkinson's Disease
  • 7.5. Epilepsy
  • 7.6. Others

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Deep Transcranial Magnetic Stimulation
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Repetitive Transcranial Magnetic Stimulation
  • 8.4. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Ambulatory Surgery Centers
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Brainsway
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Magstim
  • 12.3. Neurosoft
  • 12.4. MAG & More GmbH
  • 12.5. Salience TMS Neuro Solutions
  • 12.6. eNeura Inc.
  • 12.7. Nexstim, Inc
  • 12.8. Magventure
  • 12.9. Eneura
  • 12.10. Axilum Robotics

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us